- Home
- WVE vs GSL Comparison
WVE vs GSL Comparison
Compare WVE & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- GSL
- Stock Information
- Founded
- WVE 2012
- GSL 2007
- Country
- WVE Singapore
- GSL Greece
- Employees
- WVE N/A
- GSL N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- GSL Marine Transportation
- Sector
- WVE Health Care
- GSL Consumer Discretionary
- Exchange
- WVE Nasdaq
- GSL Nasdaq
- Market Cap
- WVE 915.6M
- GSL 1.1B
- IPO Year
- WVE 2015
- GSL 2006
- Fundamental
- Price
- WVE $8.29
- GSL $31.40
- Analyst Decision
- WVE Strong Buy
- GSL Strong Buy
- Analyst Count
- WVE 17
- GSL 1
- Target Price
- WVE $19.94
- GSL $33.00
- AVG Volume (30 Days)
- WVE 2.2M
- GSL 329.1K
- Earning Date
- WVE 07-30-2025
- GSL 08-05-2025
- Dividend Yield
- WVE N/A
- GSL 6.69%
- EPS Growth
- WVE N/A
- GSL 19.05
- EPS
- WVE N/A
- GSL 10.76
- Revenue
- WVE $93,946,000.00
- GSL $730,277,000.00
- Revenue This Year
- WVE N/A
- GSL $5.44
- Revenue Next Year
- WVE $10.02
- GSL N/A
- P/E Ratio
- WVE N/A
- GSL $2.92
- Revenue Growth
- WVE N/A
- GSL 4.04
- 52 Week Low
- WVE $5.04
- GSL $17.73
- 52 Week High
- WVE $16.74
- GSL $31.41
- Technical
- Relative Strength Index (RSI)
- WVE 41.39
- GSL 69.92
- Support Level
- WVE $7.12
- GSL $29.28
- Resistance Level
- WVE $10.45
- GSL $30.78
- Average True Range (ATR)
- WVE 0.54
- GSL 0.53
- MACD
- WVE -0.24
- GSL 0.02
- Stochastic Oscillator
- WVE 33.82
- GSL 99.53
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.